Outcomes of coronavirus disease 2019 (COVID‐19) and risk factors associated with severe COVID‐19 in patients with mature B‐cell non‐Hodgkin lymphomas: A US electronic health record cohort study

OBJECTIVES: The objectives of this study were to assess the risk of severe coronavirus disease 2019 (COVID‐19) outcomes in patients with mature B‐cell non‐Hodgkin lymphoma (mature B‐cell NHL) compared with other cancers and to identify risk factors associated with severe COVID‐19. METHODS: This study used Optum's electronic health record database. Risk factors were evaluated using multivariable logistic regression. RESULTS: Patients with mature B‐cell NHL were more likely to be hospitalized or die from COVID‐19 (age‐ and sex‐standardized risk: 15.6%, 2.1%, respectively) than those without cancer (9.5%, 1.2%), or with solid tumors (9.7%, 1.3%). In patients with mature B‐cell NHL, factors associated with severe COVID‐19 outcomes included: greater age (75–84 years, adjusted odds ratio, 1.6 [95% CI, 1.3–2.0]; ≥85, 2.6 [2.0–3.4]), male sex (1.4 [1.2–1.6]), chronic kidney disease (1.4 [1.1–1.7]), chronic obstructive pulmonary disease (1.3 [1.0–1.6]), type 2 diabetes (1.3 [1.1–1.5]), and receiving treatment for NHL (1.5 [1.1–2.1]). CONCLUSIONS: These data suggest that patients with mature B‐cell NHL are at a higher risk of severe COVID‐19 than patients with solid tumors or without cancer and that risk factors are largely consistent with those in the general population.